Effectiveness of Antiviral Drugs Against Monkeypox Uncertain

By Ernie Mundell
HealthDay Reporter

WEDNESDAY, May 25, 2022 (HealthDay News) — Up until recently monkeypox infection outside of Africa was rare, but a look back at seven cases occurring in Britain over the past few years gives hints at what drugs work to fight the disease — and which don’t.

The need to better understand treatments for monkeypox became more urgent this month when more than a hundred new cases were recorded across Europe and North America.

“As public health officials are trying to understand what is causing the May 2022 monkeypox outbreaks in Europe and North America — which have affected several patients who reported neither travel nor an identified link to a previously known case — our study offers some of the first insights into the use of antivirals for the treatment of monkeypox in humans,” said study lead author Dr. Hugh Adler. He’s with the Liverpool University Hospitals NHS Foundation Trust.

The new analysis, published May 24 in The Lancet Infectious Diseases, looked at outcomes for seven people treated in Britain for monkeypox between 2018 and 2021. Three patients were thought to have become infected while in Africa, while three more occurred as part of a “case cluster” in Britain.

According to a Lancet news release, one more case “occurred in a health care worker 18 days after initial exposure to the virus and was the first example of monkeypox transmission in a hospital setting outside of Africa.”

Two antiviral medications used against smallpox, brincidofovir and tecovirimat, were used “off-label” — meaning they are not specifically approved to treat monkeypox — as treatment in the monkeypox cases.

Speaking at a U.S. Centers for Disease Control and Prevention press conference on Monday, Dr. Brett Petersen, a medical officer with the agency’s Poxvirus and Rabies Branch said both of these antivirals could be tried against cases that are newly emerging in the United States.

Tecovirimat has already gotten expanded access approval by the U.S. Food and Drug Administration to treat monkeypox, he noted. The CDC is working to get similar emergency access approval for the newer smallpox medication, brincidofovir.

The British researchers noted there are currently no licensed treatments in the United Kingdom for monkeypox, and it’s uncertain how long the disease is contagious. Patients are typically placed in isolation in the hospital while treatment occurs.

According to Adler’s team, only one of the two antivirals appeared to have any benefit in curbing monkeypox.

Used a week after the onset of the typical monkeypox rash, brincidofovir “was not observed to have any convincing clinical benefit in treating monkeypox and alterations in liver blood tests were observed,” according to the release.

In any case — and as often happens — all four patients who got brincidofovir did make a full recovery from their illness, the researchers noted.

On the other hand, one patient treated in 2021 with the other antiviral, tecovirimat, “experienced a shorter duration of symptoms and upper respiratory tract viral shedding than the other cases in this cluster,” according to the release.

However, the British team stressed that the number of patients studied remains so small that no definite conclusions can be drawn at this point in time as to what drugs might work best to shorten or ease the disease.

They noted all of the patients experienced “mild” cases of monkeypox, and none developed severe complications such as pneumonia or sepsis (blood infection). One patient did develop an abscess that required drainage, and another suffered a relapse about six weeks after hospital discharge.

New information on how long a patient might remain infectious with monkeypox did emerge from the study.

“During previous outbreaks of monkeypox, patients were considered infectious until all lesions crusted over. In these seven UK cases, viral shedding was observed for at least three weeks following infection. However, data on infectivity remains limited, and is an important area for future study,” study co-author Dr. Catherine Houlihan said in the release. She’s with the UK Health Security Agency and University College London.

According to the study authors, typical symptoms of monkeypox include fever, rash, and swollen lymph nodes. Complications can sometimes occur, such as inflammation of the lungs, inflammation of the brain, vision-threatening inflammation of the cornea, and secondary bacterial infections.

The current outbreak affecting the United States, Canada, Britain and some other European countries is troubling because patients typically did not contract the illness while in Africa.

However, “although this latest outbreak has affected more patients than we had previously encountered in the UK, historically monkeypox has not transmitted very efficiently between people, and overall the risk to public health is low,” Adler said in the journal release.

Speaking at the Monday CDC briefing, one agency expert echoed those sentiments.

“The strain in the identified cases, both in the United States and globally, is West African strain, which is the milder of the two strains of monkeypox virus,” said Capt. Jennifer McQuiston, deputy director of the agency’s Division of High Consequence Pathogens and Pathology.

“Most people who are infected with monkeypox recover within two to four weeks without specific treatment,” she said.

More information

The U.S. Centers for Disease Control and Prevention has more about monkeypox.

SOURCES: The Lancet Infectious Diseases, news release, May 25, 2022; U.S. Centers for Disease Control and Prevention media briefing, May 23, 2022

Source link

19 thoughts on “Effectiveness of Antiviral Drugs Against Monkeypox Uncertain

  • December 16, 2023 at 10:12 am

    Great wordpress blog here.. It’s hard to find quality writing like yours these days. I really appreciate people like you! take care

  • January 10, 2024 at 10:29 am

    Do you have a spam issue on this site; I also am a blogger, and I was wondering your situation; we have developed some nice methods and we are looking to swap solutions with others, why not shoot me an email if interested.

  • January 10, 2024 at 3:15 pm

    Great write-up, I am regular visitor of one?¦s blog, maintain up the excellent operate, and It is going to be a regular visitor for a long time.

  • January 19, 2024 at 9:24 pm

    I would like to thnkx for the efforts you have put in writing this blog. I am hoping the same high-grade blog post from you in the upcoming as well. In fact your creative writing abilities has inspired me to get my own blog now. Really the blogging is spreading its wings quickly. Your write up is a good example of it.

  • January 20, 2024 at 6:47 pm

    It¦s in point of fact a nice and helpful piece of info. I¦m glad that you simply shared this helpful info with us. Please stay us up to date like this. Thanks for sharing.

  • February 8, 2024 at 8:21 am

    I am continually looking online for ideas that can benefit me. Thanks!

  • February 8, 2024 at 5:41 pm

    Great wordpress blog here.. It’s hard to find quality writing like yours these days. I really appreciate people like you! take care

  • March 6, 2024 at 10:11 pm

    Hi there! I know this is kind of off topic but I was wondering if you knew where I could get a captcha plugin for my comment form? I’m using the same blog platform as yours and I’m having difficulty finding one? Thanks a lot!

  • March 10, 2024 at 7:06 am

    Hi this is kinda of off topic but I was wondering if blogs use WYSIWYG editors or if you have to manually code with HTML. I’m starting a blog soon but have no coding know-how so I wanted to get guidance from someone with experience. Any help would be greatly appreciated!

  • March 11, 2024 at 6:14 pm

    Hi, Neat post. There is an issue together with your web site in web explorer, could check this… IE nonetheless is the market chief and a good element of people will pass over your wonderful writing because of this problem.

  • March 12, 2024 at 7:29 am

    I’ve read several good stuff here. Certainly price bookmarking for revisiting. I wonder how a lot effort you place to make this type of magnificent informative website.

  • March 21, 2024 at 11:38 am

    Write more, thats all I have to say. Literally, it seems as though you relied on the video to make your point. You obviously know what youre talking about, why throw away your intelligence on just posting videos to your weblog when you could be giving us something informative to read?

  • March 30, 2024 at 4:55 am

    Great info and straight to the point. I don’t know if this is truly the best place to ask but do you people have any thoughts on where to employ some professional writers? Thank you 🙂

  • April 10, 2024 at 4:27 am

    I’d have to examine with you here. Which is not one thing I usually do! I take pleasure in reading a post that may make folks think. Additionally, thanks for permitting me to comment!

  • April 15, 2024 at 12:00 am

    I have been exploring for a little bit for any high quality articles or weblog posts on this kind of area . Exploring in Yahoo I eventually stumbled upon this website. Reading this info So i¦m glad to exhibit that I have an incredibly excellent uncanny feeling I came upon exactly what I needed. I such a lot certainly will make sure to don¦t fail to remember this web site and give it a glance regularly.

  • April 15, 2024 at 11:28 am

    I would like to thnkx for the efforts you have put in writing this blog. I am hoping the same high-grade blog post from you in the upcoming as well. In fact your creative writing abilities has inspired me to get my own blog now. Really the blogging is spreading its wings quickly. Your write up is a good example of it.

  • April 16, 2024 at 6:52 am

    Amazing! This blog looks just like my old one! It’s on a totally different subject but it has pretty much the same layout and design. Wonderful choice of colors!

  • April 16, 2024 at 5:53 pm

    This is a topic close to my heart cheers, where are your contact details though?

Leave a Reply

Your email address will not be published.